FDA Moves to Cut Costs for Biosimilar Drug Development

PK Studies in the Crosshairs: FDA Revises Biosimilar Development Guidance

The FDA continues to refine its approach to biosimilar development. On March 9, 2026, the Agency announced the release of the revised draft guidance titled “New and Revised Draft Q&As on Biosim…

FDA Moves to Cut Costs for Biosimilar Drug Development

WASHINGTON, D.C. — The U.S. Food and Drug Administration announced new draft guidance aimed at reducing the cost and complexity of developing biosimilar medicines, a move the agency says could help expand access to lower-cost alternatives to expensive biologic drugs. What This Means for You Drug developers may face fewer testing requirements when creating biosimilar medicines. The changes could reduce certain study costs by up to 50%, potential…